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Abstract
Progressive neuronal loss is a typical characteristic of neurodegenerative diseases. 
In Parkinson’s disease, the loss of dopaminergic neurons in the basal ganglia results 
in impaired mobility and flawed muscle control. The loss of cholinergic neurons 
largely in the basal forebrain contributes to memory and attention deficits and the 
overall cognitive impairment in Alzheimer’s disease. This being said, neuroprotec-
tive drugs should be expected to preserve and/or restore the functions affected by 
neuronal loss, and substantially prevent cell death. The endocannabinoid system, 
comprising lipid mediators able to bind to and activate cannabinoid receptors, 
has emerged as a therapeutic target of potential interest in a variety of central 
nervous system diseases. Palmitoylethanolamide (PEA) is one of the most impor-
tant endocannabinoids, which has a key role in modulating oxidative stress and 
inflammatory response with neuroprotective potential in neurological disorders. 
Neurodegenerative diseases undergo varied, progressive stages. The current thera-
peutical approaches are beginning to fall short when it comes to meet the expected 
results, urging to either develop or identify or develop new effective treatments. This 
chapter discusses the neuroprotective potential of new drugs, aiming to shed some 
light on their proposed mechanism of action and their effect in cellular and animal 
models of neurodegeneration.
Keywords: Parkinson’s disease, Alzheimer’s disease, endocannabinoids, 
palmitoylethanolamide (PEA), dopaminergic neurons
1. Introduction
The palmitoylethanolamide (PEA) is an endogenous biologically active lipids 
belonging to the family of the endogenous cannabinoid. PEA has many uses in a 
range of therapeutics areas, such as: neurological diseases, neurodegeneration,  
and pain.
Several studies have been carried out to define the molecular mechanism 
of PEA. However, at time, it was proposed that the existence of a mechanism 
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receptor-dependent, and several studies demonstrated that PEA can act via direct 
activation of two different receptors: the orphan GPCR 55 (GPR55) [1] and the 
PPAR-α [2]. It was discovered that there is a wide variety receptors capable of inter-
acting with PEA. All of them are belonged to these two receptors families, Figure 1.
Other supposition postulated that PEA could also be a cannabinoid receptor 
type 2 (CB2) receptor agonist; however, studies suggested that it has very weak 
affinity for this receptor [3]. In other hand, the transient receptor potential vanil-
loid receptor type 1 (TRPV1) channels can be activated for PEA in an indirectly 
way, Figure 1. These receptors are important targets of many endocannabinoids.
All data, which will be shown in this chapter, suggest that the action mechanism 
of PEA operates for several different ways. In the central and the peripheral nervous 
system, these mechanisms have collaborative interactions essential for the most 
important therapeutic effects of PEA.
2. Receptors of PEA
GPR55 and PPAR-α are the two most important receptors for PEA. GPR55 is a 
receptor belongs to the large family of GPCRs. It is expressed in brain areas, includ-
ing the hippocampus, striatum, cortex, forebrain, and cerebellum. It has been 
reported that GPR55 utilizes the high concentration of intracellular to trigger a 
cascade of signalling events [4]. NF-κB, cAMP, MAPK, ERK1/2, and transcriptional 
regulators such as nuclear factor of activated T-cells (NFAT) are involved to GPR55 
activation [5]. Other receptor belongs to the family of GPCR is GPR119, which can 
recognize oleoylethanolamide (OEA) and PEA. However, these two acylethanol-
amides do not interact with classical cannabinoid receptors such as CB1 and CB2 [6].
PPAR-α belongs to the family of PPARs and acts as a nuclear receptor protein. 
PPAR-α is present in many tissues and organs; liver, intestine, heart, muscle, 
Figure 1. 
Scheme of the performance of the PEA through the union to its different receptors. The PEA, through PPARα, 
mainly performs metabolic functions such as the regulation of lipid metabolism and exerts neuroprotective 
functions due to the reduction of transcription of various proinflammatory cytokines. After the binding of PEA 
to PPARα in the nucleus, it heterodimerizes with the RXR receptor, to then join specific DNA sequences called 
PPRE. These PPRE modulate transcription of target genes that control a wide variety of activities metabolic 
and physiological. On the other hand, it has been hypothesized that the PEA can also exercise its biological 
functions through different transmembrane receptors like GPR55, GPR119, and TRPV1, although this issue is 
still controversial.
3
Neuroprotective Properties of Cannabinoids in Cellular and Animal Models: Hypotheses and Facts
DOI: http://dx.doi.org/10.5772/intechopen.90761
brain, kidney, and adipose tissue. Also, this receptor is present in cells of the 
immune system PPAR-α. Their main functions are involved in the control of 
inflammatory processes and in the transcription factor regulating gene expres-
sion. In the same way, it is accepted that the binding of PEA to PPAR-α induces 
a heterodi-merization event with the retinoic acid receptor (RXR), forming the 
activated receptor complex, which decrease the transcription of pro-inflammatory 
genes [7].
Both receptors have recently emerged as a putative target for the treatment of 
pain, inflammation, and neurodegenerative diseases [8].
3. Other components involved indirectly in the mechanism of PEA
TRPV1 channel belongs to a subfamily of transient receptor potential channels 
(TRP channels). It is called ‘the capsaicin receptor.’ This is conformed by intramem-
brane loop linking the transmembrane domains, forming the pore channel region 
[9]. TRPV1 is present in sensory nerve fibres and dorsal root ganglia, keratinocytes, 
in brain neurons, and other cell types [10–13]. TRPV1 is activated by stimulation of 
the non-selective ion channel, permeable to cations. Also, it is activated by exog-
enous or endogenous chemical compounds [9, 14].
The changes in the phosphorylation state of TRPV1 induced by regulatory 
proteins (including PKA, PKC, ATP, phosphorinositide binding protein (PIRT) 
and phosphatidylinositol 4,5-bisphosphate (PIP2)) influent in the function of the 
receptor [15, 16]. The changes in the phosphorylation state produce an activation of 
TRPV1, then this trigger the signaling cascade to pain transmission, neurotoxicity, 
and inflammation [13, 17]. The high concentration of intracellular Ca2+ produces 
the stimulation of two processes very important. On the one hand, the stabiliza-
tion of the channel by locked conformational. On the other hand, the inactivation 
of TRPV1 channel by Ca2+-dependent phosphatases, such as calcineurin, which 
dephosphorylate it [15, 16]. This process contributes to the anti-inflammatory and 
analgesic actions of TRPV1 [16, 17].
There are many hypotheses about the mechanisms for the action of PEA with 
TRPV1 channels. One of them proposes that TRPV1 channels can be indirectly 
activate via PPAR-α due the action of PEA. Other mechanism proposes an indi-
rectly activation of TRPV1 through the allosteric effects produce for PEA. It could 
increase AEA - or 2-AG induced activation and desensitization at TRPV1 channels 
[10, 18, 19].
The cannabinoid receptors types 1 and 2 (CB1 and CB2) are members of the 
G protein coupled receptor (GPCR) family that were identified over 20 years ago. 
[20, 21]. The CB1 receptor is often expressed in the brain, in the peripheral nervous 
system and presynaptic terminals. Also, it is expressed in almost all mammalian 
tissue and organs [22]. Its activation usually inhibits neurotransmitter release; the 
CB1 activation inhibits adenylate cyclase activity with the subsequent stimulates 
MAPK activity or reduction of intracellular levels of cAMP [23]. Consequently to 
the coupling of CB1 to PKB (Akt), phosphoinositide 3-kinase and PLC/inositol1, 
4,5-trisphosphate/PKC (PLCβ/IP3/PKC) pathways [24, 25].
The CB2 receptors are involved in the activated astrocytes and microglia in the 
brain, where are expressed in low concentration [26]. However, this receptor is 
expressed in peripheral organs and cells of the immune system [16, 27–29]. One 
of the most important functions of the CB2 receptor is controlling the inflamma-
tory responses [16, 30]. The CB2 receptor activation promotes MAPK activity and 
inhibits adenylate cyclase activity [31].
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CB1 and CB2 can be indirectly activated by PEA through several of the mecha-
nisms, although they are not direct targets [3, 12, 19, 32].
4. Brain injury and hypoxia ischemia
There are different causes of brain injury. However, none of them have a specific 
and efficient treatment to reverse its effects. The hypoxia-ischemia (HI) is one of 
the most important causes of neuronal damage and this will be the focus of this 
section.
HI impairs normal blood flow and reduces the oxygen and glucose supply to 
cells. This affects the cellular energy demand through alterations of aerobic metabo-
lism, mitochondrial oxidative phosphorylation, and the anaerobic glycolysis [33]. 
Even though a HI event affects the heart, liver, kidneys, gut, and every other organ, 
it poses the central nervous system (CNS) to severe danger, as shown in human and 
animal models [33, 34]. The mechanism of brain injury involves a series of events 
referred to as the “excito-oxidative cascade”; it triggers the activation of excitatory 
glutamate receptors leading to excessive neuronal calcium influx. Calcium flooding 
through NMDA channels activates nitric oxide synthase raising the concentration of 
the free radical nitric oxide to toxic levels. The increase of both nitrogen- and  
oxygen-free radical species generated during the post-hypoxic re-oxygenation phase 





• Bilateral common carotid artery (CCA) 
occlusion combined with systemic 
hypotension, hypoxia or anoxia: this 
model results in variable ischemia 
depending on how long hypotension, 
hypoxia or anoxia last in neonatal rats
• Permanent middle cerebral artery 
(MCA) occlusion: electrocauterization 
of the MCA proximal to the origin of the 
lateral lenticulostriate arteries
• Four vessel occlusions: A cauterizing 
needle causes blood electrocoagulation 
in the vertebral arteries, with clamps 
around the CCAs. The experimenter 
manipulates the clamps through an 
incision in the neck of adult rats, 
tightening the clamps 24 h later
• Transient middle cerebral artery (MCA) 
occlusion: Ligation with surgical clips or 
sutures
• Uterus horns immersion: It consists 
of removing uterus horns containing 
fetuses from ready-to-deliver rats and 
immersing them in a water bath at 
37°C for 5–20 min. The degree of HI is 
proportional to the immersion span
• Non-invasive model using intralumi-
nal sutures: It consists of inserting a 
nylon filament through the proximal 
external carotid artery to occlude the 
MCA. Reperfusion follows later suture 
removal
Cell culture • Cell culture models. There are a few 
cell cultures models that mimic the 
hypoxic–ischemic injury. Among them, 
oxygen and glucose deprivation (OGD) 
is a widely used in vitro model of 
ischemia that results in apoptotic and 
necrotic cell death
Table 1. 
Animals and cellular models to hypoxia-ischemia: in the table are showed the most used models for global and 
focal hypoxia ischemia.
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and electron transport. Calcium toxicity is also mediated by activation of other 
enzymes including caspases, calpains and other proteases, and lipases, which attack 
mitochondria and other cellular machinery. As a result, the damaged mitochondria 
release signals leading to apoptosis or programmed cell death as long as the energy 
supplies persist, and otherwise to necrosis and destruction of cellular membranes 
when energy becomes exhausted. Impairment of mitochondrial oxidative phos-
phorylation results in lactic acid accumulation, which may be less toxic in the 
neonatal brain compared with the adult brain.
The extent of damage to the central nervous system determines whether global 
or focal HI takes place. The focal hypoxia-ischemia occurs when an end artery is 
exclusively occluded. However, the spread of damage depends on the duration and 
degree of the occlusion and on how well the collateral irrigation copes with meta-
bolic demands. In two brain areas, the core and the penumbra are found the most 
evident effect of damage. In the core area, the collateral blood supply is reduced and 
shows the most severe and irreversible lesions. The penumbra surrounds the core 
area and receives collateral irrigation, reducing its vulnerability to the occlusion. 
Consequently, penumbra cells either recover from the transient damage or start a 
series of events that ultimately lead to cell death [35].
Global cerebral HI remains a superlative cause of perinatal brain injury, ulti-
mately leading to neurologic dysfunction, which becomes manifest as cerebral 
palsy, mental retardation, and epilepsy [36, 37]. Encephalopathy following peri-
natal HI occurs in 1–3 per 1000 term births in the United Kingdom [38]. Similarly, 
stroke affects 15 million people worldwide each year and is the leading cause of 
disability in the United States of America [39].
Different models are used to investigate the pathophysiology of HI. Even though 
none of them strictly reproduce the clinical conditions, however, they are used 
to study cellular and molecular mechanisms underlying HI and test the potential 
therapeutic agents, Table 1.
5. PEA and Hypoxia—Ischemia
From the 1970s, our understanding of the pathogenesis of the hypoxia-ischemia 
(HI) brain injury has grown considerably [40], both in the physiological and 
molecular aspects. This progress has taken us closer to develop different therapies 
to prevent or minimize neuronal HI damage. In this regard, the hypothermia, nitric 
oxide synthase inhibitors, and neuronal growth factors that help neuronal survival 
and may play a role in rescuing brain tissue and promoting brain growth following 
injury and blocking HI apoptosis by caspase inhibition [36]. Hypothermia is one of 
the few strategies applied in the clinical treatment of perinatal brain injury due to 
both HI and stroke [41]. With the advance in molecular science, pharmacology, and 
genomics, new therapeutic approaches are arising. Accordingly, pharmacogenomics 
has gathered the interest of many groups allowing individualized treatment and 
maximizing therapeutic effects while minimizing side effects [42].
The treatment with PEA has been used in cellular and animal models. Rats 
were exposed to neonatal anoxia-ischemia (AI) and then treated with vehicle or 
PEA showed that neonatal AI was associated with decreased locomotion, as well 
as recognition and spatial memory impairments. Furthermore, these deficits 
were accompanied with enhanced neuroinflammation and astrogliosis, as well as 
a decreased PPARα expression. PEA treatment was able to prevent neuroinflam-
mation, reduce astrogliosis, and preserve cognitive functions [43]. In addition, 
it has also been shown that in a mice model of perinatal hypoxic-ischemic (HI) 
encephalopathy, PEA exert neuroprotective effects on cultured cortical neurons 
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being mediated by TRPV4 receptor, and cotreatment with OEA and PEA is able to 
enhance neuroprotective effects of the acylethanolamides [18]. A neuroprotective 
function of injected PEA and OEA has been substantiated in mice with transient 
middle cerebral artery occlusion [44, 45], but both in the OEA and in the PEA, the 
mechanism by which they would be exercising their neuroprotective actions would 
be through PPARα activation [44]. Besides, PEA may potentiate microglial cell 
motility after focal cerebral ischemia by an apparent non-cannabinoid receptor-
mediated mechanism [46]. PEA exerts neuroprotection and reduces inflamma-
tory secondary events associated with brain ischemia reperfusion injury (middle 
cerebral artery occlusion (MCAo)), in rats subjected to MCAo and treated with 
PEA in conjunction with Luteolin post-ischemia showed reduced edema and brain 
infract volume, improved neurobehavioral functions, and reduced expression of 
pro-inflammatory markers and astrocyte markers. In the same sense, a cohort of 
250 stroke patients undergoing neurorehabilitation on either an inpatient or an 
outpatient basis that were treated for 60 days with a pharmaceutical preparation 
of PEA and luteolin improved the neurological status, impairment of cognitive 
abilities, the degree of spasticity, pain, and independence in daily living activities 
[47]. PEA-mediated improvements in tissues histology shown by reduction of lesion 
size and improvement in apoptosis level (assayed by Bax and Bcl-2) further support 
the efficacy of PEA therapy in MCAo mice. PEA treatment blocked infiltration of 
astrocytes and restored MCAo-mediated reduced expression of PAR, nitrotyrosine, 
iNOS, chymase, tryptase, growth factors (BDNF and GDNF), and GFAP and also 
inhibited the MCAo-mediated increased expression of pJNK, NF-kB, and degrada-
tion of IkB-a, as well as improved neurobehavioral functions as evaluated by motor 
deficits [48]. In perinatal asphyxia (PA) murine model, PEA attenuated PA-induced 
cellular and molecular hippocampal damage and its corresponding behavioral 
alterations. PEA treatment improved dendritic cytoskeleton alteration in CA1 
hippocampal area evidenced by the increase of MAP-2 and the reduction of pNF-
H/M immunostaining and protein expression levels, as well as, vertical exploration 
impairments and anxiety-related behaviors [49]. On the other hand, in a cellular 
oxygen and glucose deprivation (OGD) model that mimics brain-ischemia, PEA 
and luteolin pre-treatment synergistically prevented the OGD-induced degranula-
tion of mast cells and reduced the neurotoxic potential of MC/9 cells conditioned 
medium as well as pure neurons susceptibility to OGD [50].
6. PEA and neurodegenerative diseases
Many neurodegenerative diseases are characterized by loss of the functions of 
the nervous system causes for neuronal disorders or damage. The most frequently 
diseases are Alzheimer’s disease (AD) and Parkinson’s disease (PD). The effect of 
the damage can lead to loss of the mobility, behavioral disorders, and dementia.
The effects of PEA were demonstrated in several assays. To AD, for example, it 
was registered in a mouse model, that administration of the PEA produces a reduc-
tion in the behavioral impairments [51].
In assays in vivo using adults’ male rats, which consisted in the intrahippo-
campal injection of amyloid-β1–42 (Aβ1–42) peptide, the administration of PEA 
affected in: the high transcription and expression of GFAP and S100β (activators 
of astrocytes), the increased expression of BACE1 and APP (amyloidogenic), and 
phosphorylated τ proteins. Also, PEA changed the altered expression of microtu-
bule-associated protein (MAP-2) and cognitive functions induced [52].
An animal PD model that use the injection of the neurotoxin 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) has been showed the neuroprotective 
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actions of PEA [53]. A treatment with PEA neutralizes the activation of astrocytes 
and expression of iNOS protein, the loss of nigrostriatal neurons, and the expres-
sion of microtubule-associated, produced by MPTP in the model. In other hand, 
PEA decreased the motor dysfunctions associated to the MPTP effects. The acti-
vation of PPAR-α was a key piece in the PEA effects [53]. On the other hand, in 
cellular models, PEA has been shown to have protective effect on SH-SY5Y neu-
roblastoma against 6-OHDA damage, partly by inhibiting endoplasmic reticulum 
stress detrimental response [54].
Therapeutic effects of PEA have also been reported in several chronic models 
of MS, such as chronic relapsing experimental autoimmune encephalomyelitis 
(CREAE), Theiler’s murine encephalomyelitis virus-induced demyelinating disease 
(TMEV-IDD), and myelin oligodendrocyte glycoprotein-induced experimental 
autoimmune encephalomyelitis (MOG-EAE). In an animal model of chronic relaps-
ing experimental allergic encephalomyelitis induced by repeated administration to 
mice of syngenic spinal cord homogenate emulsified in Freund’s complete adjuvant, 
it was demonstrated that PEA alleviated the spasticity found in the hind limbs [55] 
and also in TMEV-IDD, respectively [56]. These effects of PEA are due in large part 
to their anti-inflammatory effects. In both CREAE and TMEV-IDD, a reduction in 
proinflammatory cytokines was observed, accompanied by a decrease in damage 
and axonal demyelination [56, 57]. On the other hand, in a mouse, significantly 
reduces the development of clinical signs in the MOG model of EAE accompanied 
Figure 2. 
Schematic representation of inhibitory effect of palmitoylethanolamide (PEA) on neuroinflammation in 
neurodegenerative disorders such us hypoxia-ischemia. Neuroinflammation is a common process both for 
neurodegenerative diseases and for hypoxia-ischemia. This process consists of an inflammatory response 
carried out by both astrocytes and microglia cells through the release of proinflammatory cytokines, neurotoxic 
mediators, TNFalpha, and IL-beta. These latter throughout the activation of their own receptors trigger 
intracellular mechanisms conveying in protein degradation, mitochondria desorganization, axonal dysfunction, 
and apoptosis, with consequent neurodegeneration at the basis of diseases like Parkinson, Alzheimer, multiple 
and amyotrophic lateral sclerosis and hypoxia-ischemia. The PEA through the PPARα activation inhibits the 
neuroinflammatory process through the increase in the production of anti-inflammatory cytokines, the synthesis 
of IkB-α, as well as, favoring the increase of the synthesis of neurotrophic mediators such as: GDNF and BDNF.
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by a reduction in transcript expression of the acute-phase protein SAA1, TNF-α, 
IL-1β, IFN-γ, and NLRP3 proinflammatory proteins and TLR2, Fpr2, CD137, CD3-γ, 
TCR-ζ chain, and CB2 receptors [58]. In addition, PEA and PPAR-α (peroxisome 
proliferator-activated receptor-α agonist) have been effective in reducing symptoms 
of central neuropathic pain in patients with multiple sclerosis [59].
All these evidences suggest that PEA is a central and promising target in the 
development of new neuroprotective agents, being PPAR-α the main mechanism 
by which this neuroprotection would be being exercised. The block or mimic PEA 
effects were evidenced for the use of PPAR-α agonists and antagonists, supporting 
this idea [7, 60, 61]. Figure 2 schematizes how the mechanism of action of PEA is in 
neurodegenerative diseases such as hypoxia-ischemia.
7. Conclusion
PEA is involved in several processes: lipidic metabolism, proinflammatory 
cytokine genes transcription, signaling cascade, and proliferation. PEA is expressed 
in brain, skin, liver, intestine, heart, muscle, kidney, and adipose tissue.
It plays a protective role in several neurological disorders and ischemic brain 
injury. In vivo assays with PEA treatment showed an improve of the neuroinflam-
mation, reduce astrogliosis, and preserve cognitive functions by PPAR-α activation. 
In vitro assays, pretreatment with PEA and a flavonoid prevent the degranulation of 
mast cells and reduce the neurotoxic potential of MC/9 cells in OGD model.
PEA treatment could be a potential alternative therapy than hypothermia. This 
is because the hypothermia is an unspecific treatment and PEA acts under specific 
mechanism. However, this sort of therapy is still incipient, to say the least, and 
further investigations should pursue on focusing in the main downstream effectors 
involved in HI.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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